Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Dr Reddy's Laboratories's Other Stockholders Equity for the quarter that ended in Jun. 2026 was ₹12,125 Mil.
Dr Reddy's Laboratories's quarterly Other Stockholders Equity
increased
from Dec. 2025 (₹8,169 Mil) to Mar. 2026 (₹10,543 Mil) and
increased
from Mar. 2026 (₹10,543 Mil) to Jun. 2026 (₹12,125 Mil).
Dr Reddy's Laboratories's annual Other Stockholders Equity
declined
from Mar. 2024 (₹3,859 Mil) to Mar. 2025 (₹3,740 Mil) but then
increased
from Mar. 2025 (₹3,740 Mil) to Mar. 2026 (₹10,543 Mil).
Dr Reddy's Laboratories Other Stockholders Equity Related Terms
Dr Reddy's Laboratories Other Stockholders Equity Historical Data
* Premium members only.
The historical data trend for Dr Reddy's Laboratories's Other Stockholders Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Dr Reddy's Laboratories Other Stockholders Equity Chart
What does a Other Stockholders Equity of ₹12,125 Mil mean?
Dr Reddy's Laboratories (NSE:DRREDDY) has a Other Stockholders Equity of ₹12,125 Mil as of Jun. 2026. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Dr Reddy's Laboratories and its competitors.
Is Dr Reddy's Laboratories' Other Stockholders Equity too high?
Dr Reddy's Laboratories' current Other Stockholders Equity is ₹12,125 Mil. Overall, Dr Reddy's Laboratories has a GF Score™ of 92/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Dr Reddy's Laboratories' Other Stockholders Equity compare to ZTS and UTHR?
Dr Reddy's Laboratories' Other Stockholders Equity of ₹12,125 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Drug Manufacturers company?
A good Other Stockholders Equity depends on the Drug Manufacturers industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Dr Reddy's Laboratories and its competitors. Dr Reddy's Laboratories's current Other Stockholders Equity is ₹12,125 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dr Reddy's Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Dr Reddy's Laboratories (NSE:DRREDDY) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹1,361.49, compared to a current price of ₹1,151.70 — trading 15.4% below its estimated fair value. The current Other Stockholders Equity is ₹12,125 Mil. Dr Reddy's Laboratories' overall GF Score™ is 92/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For Dr Reddy's Laboratories (NSE:DRREDDY), the current Other Stockholders Equity is ₹12,125 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Dr Reddy's Laboratories (NSE:DRREDDY) Overvalued in 2026?
Based on GuruFocus' analysis, Dr Reddy's Laboratories stock appears to be undervalued.
The current stock price of ₹1,151.70 is trading 15.4% below its estimated GF Value™ of ₹1,361.49.
GuruFocus considers Dr Reddy's Laboratories to be Modestly Undervalued.
Key valuation signals for NSE:DRREDDY:
Other Stockholders Equity: ₹12,125 Mil
GF Value™: ₹1,361.49 vs. price of ₹1,151.70 (15.4% below fair value)
No single metric tells the full story. See the NSE:DRREDDY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly 40% of its generics sales, with other key markets being India (20%) and Europe (20%). Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.
92GF Score
Get the complete analysis for NSE:DRREDDY
Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:DRREDDY has been successfully added to your 
